Healthcare Industry News: Cardiac Monitor
News Release - December 5, 2006
Cardiac Science Begins Shipments of Atria 3100(TM) Electrocardiograph
New ECG Features Built-In, Flexible Connectivity to Streamline Practice WorkflowBOTHELL, Wash., Dec. 5 (HSMN NewsFeed) -- Cardiac Science Corporation (Nasdaq: CSCX ), a global leader in advanced Cardiac Monitoring and external defibrillation products, announced today that it has started shipping the Burdick® Atria 3100 Electrocardiograph (ECG). This compact, easy-to-use ECG is designed for the primary care physician's office, and features on-board wired Ethernet and wireless 802.11g, making it optimal for communication with electronic medical record systems (EMRs).
The Burdick Atria 3100 ECG is the latest in a line of popular and trusted ECG devices that includes its predecessor, the Atria 3000. In 2004, the Healthcare Independent Distributors Association named the Atria 3000 Product of the Year for its innovation, ease-of-use, impact on patient care and distributor acceptance. The Atria 3100 is equipped with the same easy-to-use, clinically superior features as the Atria 3000, enhanced with easily upgrade- able, on-board connectivity features that improve practice workflow and productivity.
"Burdick has been the leading ECG brand in the primary care marketplace," said Garry Norris, vice president of marketing. "We believe this is due to our commitment to providing quality, innovation and superior service to physicians on the front-line of cardiac care. Burdick devices are known for setting the industry standard for clinical efficacy and ease-of-use.
"The enhanced features of the Atria 3100 make it an excellent ECG for family and internal medicine practices. With physicians adopting EMR systems in greater numbers, the Atria 3100 adds further value to this investment by integrating ECG results seamlessly with the IT system to drive productivity improvements across the rest of the practice," Mr. Norris added.
The Atria 3100 maintains the popular compact, easy-to-use features of its predecessor and includes enhanced communications capabilities such as wired Ethernet and 802.11g, which is the industry standard for enterprise applications and features enhanced transmission security. With this level of connectivity and security, physicians can send ECG study results directly from the Atria 3100 to their EMR or to other colleagues outside their practice via E-mail or fax. Equipped for in-field upgrades, the Atria 3100 can be easily upgraded by the physician's staff, eliminating ECG downtime.
Like all Cardiac Science electrocardiographs, the Atria 3100 utilizes the proven University of Glasgow algorithm for interpretation, providing a silent second opinion. Unlike some competitive products that limit algorithm criteria to age, the University of Glasgow algorithm, under continuous development since the 1970s, bases its analysis on five clinically significant criteria: gender, age, race, medication and clinical classification. This is critical because ECG results for patients with different demographic profiles and medical conditions can vary greatly.
About Cardiac Science Corporation
Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -- defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick®, Powerheart®, and Quinton®. Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our Atria 3100 product will be successful in the marketplace, and will facilitate increased sales of our other products, resulting in increasing revenues and profits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the 10-k filed by Cardiac Science Corporation for the year ended December 31, 2005. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Source: Cardiac Science
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
